Frederick, MD., Aug. 14, 2024 -- Veralox Therapeutics, a clinical-stage biotechnology company developing first-in-class therapies targeting the 12-lipoxygenase (12-LOX) pathway, announced that the European Medicines Agency (EMA) has granted Orphan...
Venture Partner Mike Grey named EY Entrepreneur Of The Year San Diego
Venture Partner Mike Grey named EY Entrepreneur Of The Year San Diego
